Voit, T. Et Al. 2014. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. LANCET NEUROLOGY , vol.13, no.10 , 987-996.

Voit, T., Topaloglu, H., Straub, V., Muntoni, F., Deconinck, N., Campion, G., ... De Kimpe, S. J.(2014). Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. LANCET NEUROLOGY , vol.13, no.10, 987-996.

Voit, Thomas Et Al. "Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study," LANCET NEUROLOGY , vol.13, no.10, 987-996, 2014

Voit, Thomas Et Al. "Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study." LANCET NEUROLOGY , vol.13, no.10, pp.987-996, 2014

Voit, T. Et Al. (2014) . "Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study." LANCET NEUROLOGY , vol.13, no.10, pp.987-996.

@article{article, author={Thomas Voit Et Al. }, title={Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study}, journal={LANCET NEUROLOGY}, year=2014, pages={987-996} }